Angela Thedinga
Director/Miembro de la Junta en NKARTA, INC. .
Fortuna: - $ al 31/05/2024
Perfil
Angela M.
Thedinga is currently an Independent Director at Nkarta, Inc. She previously served as the Chief Technology Officer at Adverum Biotechnologies, Inc. from 2019 to 2021 and as the Chief of Staff & VP-Program Management at Novartis Gene Therapies, Inc. from 2018 to 2019.
Ms. Thedinga holds a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from the University of Wisconsin, a graduate degree from The University of North Carolina at Chapel Hill, and an MBA from MIT Sloan School of Management.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NKARTA, INC.
-.--% | 13/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Cargos activos de Angela Thedinga
| Empresas | Cargo | Inicio |
|---|---|---|
| NKARTA, INC. | Director/Miembro de la Junta | 28/03/2022 |
Antiguos cargos conocidos de Angela Thedinga.
| Empresas | Cargo | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Director Técnico/Científico/I+D | 01/10/2021 |
| AVEXIS INC | Oficial de Recursos Humanos | 01/06/2019 |
Formación de Angela Thedinga.
| Massachusetts Institute of Technology | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
| The University of North Carolina at Chapel Hill | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Bolsa de valores
- Insiders
- Angela Thedinga
